Specify a stock or a cryptocurrency in the search bar to get a summary
Spectral Med Inc
EDTSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada. Address: 135 The West Mall, Toronto, ON, Canada, M9C 1C2
Analytics
WallStreet Target Price
2.81 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EDT
Dividend Analytics EDT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EDT
Stock Valuation EDT
Financials EDT
Results | 2019 | Dynamics |